Literature DB >> 25611110

Endocrine manifestations of von Hippel-Lindau disease.

Clarissa Cassol1, Ozgur Mete.   

Abstract

von Hippel-Lindau (VHL) disease is an autosomal dominant disorder caused by heterozygous mutations in the VHL tumor suppressor gene that is characterized by the occurrence of multiple endocrine and nonendocrine lesions. This review focuses on the endocrine manifestations of VHL disease. Pancreatic neuroendocrine proliferations (ductuloinsular complexes, islet dysplasia, endocrine microadenoma, and neuroendocrine tumors), pheochromocytomas, and extra-adrenal paragangliomas are important endocrine manifestations of VHL disease. They frequently display characteristic clinical, biochemical, and histopathologic features that, although not pathognomonic, can be helpful in suggesting VHL disease as the underlying etiology and distinguishing these tumors from sporadic cases. Recent improvements in treatment and outcomes of renal cell carcinomas have allowed pancreatic neuroendocrine tumors to emerge as a significant source of metastatic disease, making the accurate recognition and classification of these neoplasms by the pathologist of utmost importance to determine prognosis, treatment, and follow-up strategies for affected patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25611110     DOI: 10.5858/arpa.2013-0520-RS

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  10 in total

Review 1.  Von Hippel-Lindau disease: a single gene, several hereditary tumors.

Authors:  J Crespigio; L C L Berbel; M A Dias; R F Berbel; S S Pereira; D Pignatelli; T L Mazzuco
Journal:  J Endocrinol Invest       Date:  2017-06-06       Impact factor: 4.256

2.  Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association.

Authors:  Karen Gomez Hernandez; Shereen Ezzat; Chantal F Morel; Carol Swallow; Mirek Otremba; Brendan C Dickson; Sylvia L Asa; Ozgur Mete
Journal:  Virchows Arch       Date:  2015-03-24       Impact factor: 4.064

Review 3.  Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.

Authors:  Ozgur Mete; Sylvia L Asa; Anthony J Gill; Noriko Kimura; Ronald R de Krijger; Arthur Tischler
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

Review 4.  Nervous system (NS) Tumors in Cancer Predisposition Syndromes.

Authors:  Prabhumallikarjun Patil; Bojana Borislavova Pencheva; Vinayak Mahesh Patil; Jason Fangusaro
Journal:  Neurotherapeutics       Date:  2022-09-02       Impact factor: 6.088

Review 5.  A Review of Von Hippel-Lindau Syndrome.

Authors:  Neha Varshney; Amanuel A Kebede; Harry Owusu-Dapaah; Jason Lather; Manu Kaushik; Jasneet S Bhullar
Journal:  J Kidney Cancer VHL       Date:  2017-08-02

6.  Somatic VHL Mutation in a Patient With MEN1-Associated Metastatic Pancreatic Neuroendocrine Tumor Responding to Sunitinib Treatment: A Case Report.

Authors:  Jasmine Shell; Dhaval Patel; Astin Powers; Martha Quezado; Keith Killian; Paul Meltzer; Jack Zhu; Apostolos Gaitanidis; Fatima Karzai; Vladimir Neychev; Patience Green; Electron Kebebew
Journal:  J Endocr Soc       Date:  2017-07-07

Review 7.  Chromatin-Bound Cullin-Ring Ligases: Regulatory Roles in DNA Replication and Potential Targeting for Cancer Therapy.

Authors:  Sang-Min Jang; Christophe E Redon; Mirit I Aladjem
Journal:  Front Mol Biosci       Date:  2018-03-13

8.  Primary Renal Carcinoid with Bilateral Multiple Clear Cell Papillary Renal Cell Carcinomas.

Authors:  Daniel A Anderson; Maria S Tretiakova
Journal:  Case Rep Pathol       Date:  2017-05-23

9.  Von Hippel-Lindau Syndrome: Medical Syndrome or Surgical Syndrome? A Surgical Perspective.

Authors:  Danilo Coco; Silvana Leanza
Journal:  J Kidney Cancer VHL       Date:  2021-12-05

10.  Bilateral Pheochromocytomas in a Patient with Y175C Von Hippel-Lindau Mutation.

Authors:  Olga Astapova; Anindita Biswas; Alessandra DiMauro; Jacob Moalem; Stephen R Hammes
Journal:  Case Rep Endocrinol       Date:  2018-07-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.